Molecular imaging enables the search for a different kind of discovery. The kind that has the ability to have a lasting impact on the world. A true discovery. Not only is it proof of a new way to understand something hidden deep within us, it has the ability to transcend the individual to make a greater impact on all patients.

CZT is the key component to the future of nuclear medicine. Not only is it lighter and more compact than the Nal crystals used in analog technology, it is pixelated. Housed within smaller and sleeker 39 cm x 51 cm FOV Planar and SPECT detector heads, each individual detector is like the eye of a fly, with thousands of tiny 2.46 mm sized detectors working together to capture more events, more accurately. It also enables direct conversion. With CZT, each photon is directly converted into an electrical signal that accurately identifies its location and energy. This eliminates the signal loss and noise inherent in conventional SPECT/CT detection technology, recovering lost spatial and energy resolution.

Discovery NM/CT 670 CZT is the first general purpose system designed with this breakthrough detection technology. Combined with registered collimation to deliver higher resolution images, edge-to-edge performance allowing for more comfortable positioning of your patients and the latest in advanced quantitative applications provided by Xeleris, this system is capable of transforming the entire nuclear medicine experience.

THE FUTURE OF NUCLEAR MEDICINE IS HERE

Up to 75 percent reduction in injected dose or scan time²

Less than 4 minutes each for Bone SPECT and WB Bone exams³

Improved system spatial resolution, from 4.3 to 2.8 mm

Exceptional energy resolution, 6.3 percent compared to 9.5 percent

Greater than 40 percent improvement in SPECT contrast-to-noise ratio, an important factor in lesion detectability⁴

67 percent reduction in detector frame size, from 7.5 cm to 2.5 cm

Optimal FOV 25 percent greater than Nal, maintaining image quality towards smaller edges

1.4 times higher count rates than conventional technology

Easy upgrade path from Discovery 670 DR to deliver CZT technology

Low CT dose with ASiR^TM,5 technology and Q.AC

As molecular imaging continues to move toward the development of disease specific diagnoses and increasingly personalized care, clinicians are looking for technology that will get them there.For nuclear medicine, resolution is important.Early disease detection is only possible with a high system resolution that enables visualization of finer anatomic detail.In addition, research with multi-isotope exams requires precise energy resolution to reduce spillover between tracers.

With direct conversion detection, Discovery NM/CT 670 CZT has substantially improved system resolution by eliminating the signal loss and noise that comes with analog detection technology.It also uses a registered collimation design that aligns each collimator with a single detector pixel.This design eliminates the impact of collimator resolution that would normally effect the overall system resolution.The result is an improved contrast-to-noise ratio and spatial resolution down to 2.8 mm.

CZT can also simultaneously detect the energy from multiple tracers with more definition than conventional technology.Its 6.3 percent energy resolution makes it possible to explore new protocols with the variety of SPECT tracers available.

SEE EVERYTHING CLEARLY NOW

Continue your efforts to diagnose and stage disease earlier with smaller lesion detectability1

Discover new protocols enabling differential diagnosis by visualizing multiple tracers simultaneously

More accurately assess treatment response to guide your treatment planning decisions with increased quantitation accuracy6

Enhance the patient experience by completing multiple exams in a single visit and single instances on the scanner bed

Increase patient satisfaction by reducing compromised exams, limiting repeat scans

Push nuclear medicine's boundaries by developing new diagnostic services

Grow patient volumes with referring physicians that value accurate, reproducible results and the diagnostic confidence you deliver

Pursue opportunities for tracer development and better utilization of currently available tracers

Often times, the technology needed to produce a specific result has an impact on the overall experience of getting that result. Many consumer industries have had to work around the design constraints that come with analog technology. For nuclear medicine, the crystal and photomultiplier tubes have to overlap beyond the useful field of view in order to limit image degradation at the edges. This creates a significant amount of unusable dead space at the edge of the detector making some procedures difficult, at times impossible, for patients to physically endure.

With a patient-centric design, certain exams become tolerable. One such exam is a cardiac SPECT scan requiring patients to extend and hold their arms above their head for a long duration. Also, more exams become available, such as whole-body procedures for taller patients and gurney scans for larger patients.

Just like the transition from analog to digital technology in other industries, the technology required to create a digital image is lighter, and more compact, with looser constraints on system design. Using registered collimation, Discovery NM/CT 670 CZT contains detected events entirely within a single pixel aligned to one collimator hole, even at the outermost edges of the FOV. This reduction in dead space enables a system design that can get closer to anatomies and increase patient comfort.

THE BEST ANGLE FOR YOU AND YOUR PATIENT

Improve imaging results by scanning in closer proximity to your patients

Provide more tolerable exams for greater patient comfort

Expand offerings that could provide economic and clinical benefits

您用于解释和传输分子信息的应用与用于突出显示该信息的跟踪器和用于捕获的技术同样重要。

通过定量应用，您可以证明所看到的内容；更重要的是，证明无法看到的内容。该应用将在确定最佳疗程和适应治疗方面给予信心。此外，还为您提供构建准确结果的数据库所需的信息。结果可用于更顺利地通知您为每位患者做出的决策，并通知研究将制定更具体的疾病适应症。

Xeleris 是久经验证致力于核医学的工作站。Xeleris 过去通过移动应用引领潮流，并为您提供易于使用的便携工具，从而提高效率。现在，通过适用于核医学的现代定量应用，最新版本的 Xeleris 正在引领潮流；在多个护理区域中，这些应用可在易于阅读的自定义绝对定量报告方面给予您更大信心。

核医学的新时代

使用 Q.Brian准确诊断神经退行性疾病

通过使用 Q.Lung 识别 V/Q 不匹配诊断肺栓塞

使用 Q.Lung 确信地对符合肺切除手术条件的患者进行分类

使用 Q.Merix 对任何病变或器官的示踪剂摄取进行量化

借助快速、可重复和准确定量 I-123 Ioflupane 与 DaTQUANTTM，改善神经病学 SPECT 工作流程

通过使用剂量测定工具包测量示踪剂吸收随时间的变化，计划放射性同位素治疗

It takes a thoughtful mind to go in search of true discovery — a mind like yours that looks to establish new standards of care to have a lasting impact on the world around them.We appreciate your efforts to influence the future of medicine to benefits us all.

To help, we have worked with many of you to understand what obstacles stand in your way and what situations you seek.The result of our partnerships is Discovery NM/CT 670 CZT.We hope you see it as we do, as much more than another imaging product.We see it as a tool to help you to bring your theories to life.

*在临床实践中，使用 ASiR 可根据临床任务、患者身材、解剖部位和临床规范减少 CT 患者曝光剂量。应咨询放射医师和医生，以确定获得特殊诊断任务图像质量的适当剂量。

²Together with Clarity 2D and Evolution⁷ and compared to Discovery NM/CT 670 Pro/ES/DR without Clarity 2D and Evolution⁷.As demonstrated in phantom testing using NEMA IEC Body Phantom.

³Together with Clarity 2D & Evolution⁷.Compared to typical 15 minute scan on Discovery NM/CT 670 Pro/ES/DR without Clarity 2D & Evolution⁷.

⁴Demonstrated in phantom testing using NEMA IEC Body Phantom at 50% scan times with Evolution⁷.Compared to Discovery NM/CT 670 Pro/ES/DR.

*在临床实践中，使用 ASiR 可根据临床任务、患者身材、解剖部位和临床规范减少 CT 患者曝光剂量。应咨询放射医师和医生，以确定获得特殊诊断任务图像质量的适当剂量。

⁶In clinical practice, the use of Discovery NM/CT 670 CZT may improve quantitation of lesions larger than 5.5mL, depending on the clinical task, patient size, anatomical location and clinical practice.应咨询放射医师和医生，以确定获得特殊诊断任务图像质量的适当剂量。

⁷In clinical practice, Evolution options^7a (Evolution for Bone, Evolution for Cardiac, Evolution for Bone Planar) and Evolution Toolkit^7b are recommended for use following consultation of a Nuclear Medicine physician, physicist and/or application specialist to determine the appropriate dose or scan time reduction to obtain diagnostic image quality for a particular clinical task, depending on the protocol adopted by the clinical site.

^7aEvolution Options – Evolution claims are supported by simulation of count statistics using default factory protocols and imaging of 99mTc based radiotracers with LEHR collimator on anthropomorphic phantom or realistic NCAT – SIMSET phantom followed by quantitative and qualitative images comparison.

^7bEvolution Toolkit – Evolution Toolkit claims are supported by simulation of full count statistics using lesion simulation phantom images based on various radiotracers and collimators and by showing that SPECT image quality reconstructed with Evolution Toolkit provide equivalent clinical information but have better signal-to-noise, contrast, and lesion resolution compare to the images reconstructed with FBP/OSEM.